دورية أكاديمية
Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma.
| العنوان: | Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma. |
|---|---|
| المؤلفون: | Albers FC; Respiratory Medical Franchise, GSK, Raleigh, North Carolina, USA., Bratton DJ; Clinical Statistics, GSK, Uxbridge, UK., Gunsoy NB; Value Evidence and Outcomes, GSK, Uxbridge, UK., Cockle SM; Value Evidence and Outcomes, GSK, Brentford, UK., Alfonso-Cristancho R; Value Evidence and Outcomes, GSK, Philadelphia, Pennsylvania, USA., Braunstahl GJ; Department of Pulmonary Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands. |
| المصدر: | The clinical respiratory journal [Clin Respir J] 2022 Mar; Vol. 16 (3), pp. 252-258. Date of Electronic Publication: 2022 Jan 26. |
| نوع المنشور: | Journal Article; Meta-Analysis |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Publishing Country of Publication: England NLM ID: 101315570 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-699X (Electronic) Linking ISSN: 17526981 NLM ISO Abbreviation: Clin Respir J Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford : Blackwell Publishing |
| مواضيع طبية MeSH: | Anti-Asthmatic Agents*/therapeutic use , Asthma*/diagnosis, Antibodies, Monoclonal, Humanized/therapeutic use ; Double-Blind Method ; Humans ; Randomized Controlled Trials as Topic ; Severity of Illness Index ; Treatment Outcome |
| مستخلص: | Patients with severe eosinophilic asthma experience daily activity limitations and reduced productivity at work. Using anonymized individual patient-level data from two previously conducted randomized, double-blind, placebo-controlled studies (MENSA [GSK ID:115588/NCT01691521]; MUSCA [GSK ID:200862/NCT02281318]), we investigated the effect of mepolizumab on work productivity, activity limitation, symptoms, and rescue medication use. Patient-reported outcomes including Work Productivity and Activity Impairment-General Health (WPAI-GH) scores (impairment percentages, 0%-100%), global activity limitation (scale 1-4), and perceived change in activity limitation (Likert scale 1-7) since the start of the study were analyzed. WPAI-GH scores from MENSA were analyzed post hoc for employed patients using mixed model repeated measures; global activity limitation and perceived change in activity limitation from MUSCA were analyzed by ordinal logistic regression. Mean changes from baseline in daily asthma symptom scores (scale 0-5) and rescue medication use (occasions/day) were also assessed, via a post hoc meta-analysis of MENSA and MUSCA. At study end, WPAI-GH scores indicative of overall work impairment, impairment while working, and activity impairment consistently improved with mepolizumab versus placebo. Overall, 76% versus 54% of patients rated their activity as "much better," "better," or "slightly better" since the start of the study with mepolizumab versus placebo. Mepolizumab was associated with numerically larger improvements from baseline in asthma symptoms (treatment difference 0.21-0.29 points) and rescue medication use (treatment difference -0.08 to -0.22 occasions/day) versus placebo. Our results indicate that patients with severe eosinophilic asthma may experience improved activity limitation, work productivity, symptoms, and rescue medication use with mepolizumab. (© 2022 GlaxoSmithKline. The Clinical Respiratory Journal published by John Wiley & Sons Ltd.) |
| References: | Arch Public Health. 2018 Jun 28;76:30. (PMID: 29988309) Lancet Respir Med. 2017 May;5(5):390-400. (PMID: 28395936) N Engl J Med. 2014 Sep 25;371(13):1198-207. (PMID: 25199059) Asthma Res Pract. 2017 Jan 6;3:1. (PMID: 28078100) Eur Respir J. 2014 Feb;43(2):343-73. (PMID: 24337046) J Asthma Allergy. 2019 Jul 11;12:183-194. (PMID: 31372003) Pharmacoeconomics. 1993 Nov;4(5):353-65. (PMID: 10146874) Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618808490. (PMID: 30354852) Adv Ther. 2018 Jul;35(7):1059-1068. (PMID: 29949045) Clin Respir J. 2022 Mar;16(3):252-258. (PMID: 35081275) |
| معلومات مُعتمدة: | GlaxoSmithKline |
| فهرسة مساهمة: | Keywords: activities of daily living; eosinophilic asthma; patient-reported outcomes; questionnaire; symptom assessment; work productivity |
| المشرفين على المادة: | 0 (Anti-Asthmatic Agents) 0 (Antibodies, Monoclonal, Humanized) 90Z2UF0E52 (mepolizumab) |
| تواريخ الأحداث: | Date Created: 20220126 Date Completed: 20220307 Latest Revision: 20230916 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9060075 |
| DOI: | 10.1111/crj.13474 |
| PMID: | 35081275 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1752-699X |
|---|---|
| DOI: | 10.1111/crj.13474 |